This is a significant strategic entry into the TAVR market, a high-growth structural heart segment where BSX currently has no product. The SIEGEL valve's differentiated design (nickel-free, smaller sheath) and early clinical data position it as a potential competitor to Edwards and Medtronic. Watch for STAR trial enrollment updates and FDA milestone announcements as catalysts for the call option exercise. The $3.0 billion option price implies a ~$4.5 billion total enterprise value for the TAVR asset, which is reasonable given the market opportunity.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 18 $55.89entry
- T+1 · 6mo ago +1.66%α +2.31% · $56.82
- T+5 · 6mo ago +3.10%α +1.48% · $57.62
- T+20 · 5mo ago −16.33%α −18.52% · $46.76
- T+60 · 3mo ago −8.04%α −12.62% · $51.40
Price Chart
How similar events traded
Executive Summary
Boston Scientific invested $1.5 billion for a 33.75% equity stake in MiRus LLC, a privately-held developer of the SIEGEL TAVR system, and obtained an exclusive option to acquire the TAVR business for an additional $3.0 billion upon achievement of clinical and regulatory milestones. The investment provides BSX with a differentiated, nickel-free balloon-expandable TAVR valve currently in a pivotal trial, though the device remains investigational and not yet approved for commercial sale.
Key Facts
- BSX acquired 33.75% of MiRus for $1.5 billion cash (plus a prior $100 million payment) on May 15, 2026.
- BSX holds an exclusive call option to acquire the TAVR-Structural Heart NewCo for an additional $3.0 billion in cash upon milestone achievement.
- The SIEGEL TAVR valve is the first nickel-free, balloon-expandable TAVR system, delivered through an 8 French sheath (50% smaller than current sheaths).
- MiRus recently initiated the STAR pivotal trial (up to 1,025 patients) for FDA PMA approval.
- The investment is expected to be immaterial to BSX's adjusted EPS in 2026.
- If BSX does not exercise the call option, its equity stake will be forfeited or reduced by ~75%.
Financial Impact
$1.5 billion cash investment for 33.75% stake, with a potential additional $3.0 billion for full ownership of the TAVR business; immaterial to 2026 adjusted EPS.
Risk Factors
- The SIEGEL valve is investigational and not yet approved in any country; pivotal trial failure or regulatory delays could impair the investment.
- If BSX does not exercise the call option, the $1.5 billion equity stake is largely forfeited (~75% reduction), representing a substantial loss.
- Integration risk and competition from established TAVR players (Edwards, Medtronic) could limit commercial uptake even if approved.
- The $3.0 billion option payment plus potential sales-based milestones represent significant future cash outflows.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000885725-26-000041 |
| Exhibit: exhibit991-pressrelease_fi.htm | 0000885725-26-000041 |
| Document: 0000885725-26-000041-index-headers.html | 0000885725-26-000041 |
| Document: 0000885725-26-000041-index.html | 0000885725-26-000041 |
| Document: 0000885725-26-000041.txt | 0000885725-26-000041 |
Track record
22 reports on BSX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +9.24% at T+20 after the Aug 26, 2026 report. 6 of 8 went positive at some point.
Filters
- Oct 28, 202619d ago 8-K Bearish 6/10 No price data
- Oct 28, 202619d ago Press Release Bearish 5/10 Entry $42.43 Now $43.69 −2.97% settles Nov 25
- Oct 23, 202624d ago Institutional Cluster Bearish 4/10 Entry $45.69 Now $43.69 +4.38% settles Nov 20
- Oct 7, 20265w ago 8-K Mixed 6/10 Entry $41.58 to $45.82 Now $43.69 +5.07% ▲ +10.20% +11.54% vs SPY
- Sep 23, 20267w ago 8-K Bearish 5/10 Entry $44.62 to $44.51 Now $43.69 +2.08% ▲ +0.25% +0.93% vs SPY
- Aug 31, 202611w ago Court Ruling Neutral 2/10 Entry $48.08 to $43.65 Now $43.69 −9.13% ▼ −9.21% −9.57% vs SPY
- Aug 26, 202611w ago 8-K Bearish 6/10 Entry $48.17 to $43.72 Now $43.69 +9.30% ▲ +9.24% +10.44% vs SPY
- Aug 22, 202612w ago Institutional Cluster Mixed 6/10 Entry $49.01 to $44.92 Now $43.69 −10.85% ▼ −8.35% −9.66% vs SPY
- Aug 7, 202614w ago Insider Cluster Mixed 6/10 Entry $50.46 to $44.98 Now $43.69 −13.42% ▼ −10.86% −9.95% vs SPY
- Aug 7, 202614w ago Insider Cluster Mixed 5/10 Entry $50.46 to $44.98 Now $43.69 −13.42% ▼ −10.86% −9.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers